Marinus Pharmaceuticals Receives Orphan Drug Status for Ganaxolone as Treatment for Status Epilepticus

Print 18 April 2016
Robin Reyes /

Marinus Pharmaceuticals (NASDAQ:MRNS) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ganaxolone for the treatment of status epilepticus, according to the agency’s website. Status epilepticus is a dangerous condition in which epileptic seizures follow one another without recovery of consciousness between them. Ganaxolone has previously been given orphan drug designation for two other indications – as treatment for Protocadherin 19 (PCDH19) female epilepsy and as treatment for infantile spasms. MRNS shares closed at $5.17, with a 52-week range of $4.00 – $20.72.

The stock decreased 5.31% or $0.29 on April 14, hitting $5.17. Marinus Pharmaceuticals Inc (NASDAQ:MRNS) has declined 60.02% since September 9, 2015 and is downtrending. It has underperformed by 67.26% the S&P500.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. It is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of orphan disease, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing an IV formulation for use in the hospital setting to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.



All Portfolio


  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news